Kidney Disease Clinical Trial
Official title:
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
The goal of the Microalbuminuria in Untreated Boys with Alport Syndrome study is to gather
information about critical clinical time points such as when patients with small amounts of
protein (microalbuminuria) in their urine progress to larger amounts (overt proteinuria).
Large amounts of protein in the urine is often an early sign of kidney disease.
Information needs to be collected in boys who are not taking medications known as angiotensin
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in order to obtain
accurate data about the length of time between the onset of microalbuminuria and the start of
overt proteinuria. This new information will give physicians a better understanding of how to
treat patients with Alport syndrome.
The information we gather by conducting this study will aid in planning future clinical
trials because the identification of time points in disease progression, such as
microalbuminuria and overt proteinuria, could reduce the time necessary to show a clinical
benefit of a new treatment option.
The study has been approved by the University of Minnesota's Institutional Review Board.
Study Aims
1. To determine the average ages of onset of microalbuminuria and overt proteinuria in
untreated boys with Alport syndrome
2. To determine the average duration of microalbuminuria before transition to overt
proteinuria in untreated boys with Alport syndrome
This study does not involve treatment and is anticipated to last 3-5 years.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02369354 -
Transplant Social Worker Support for Live Kidney Donation in African Americans
|
N/A | |
| Not yet recruiting |
NCT02225782 -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
|
Phase 4 | |
| Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
| Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
| Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
| Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
| Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
| Terminated |
NCT00436748 -
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
| Completed |
NCT01235936 -
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
|
Phase 2 | |
| Completed |
NCT01947829 -
Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)
|
N/A | |
| Completed |
NCT01974999 -
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
|
||
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Active, not recruiting |
NCT01228903 -
Uric Acid and the Endothelium is CKD
|
N/A | |
| Completed |
NCT00734357 -
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
|
N/A | |
| Completed |
NCT00781417 -
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
|
N/A | |
| Completed |
NCT00093977 -
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT00096915 -
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
|
Phase 3 | |
| Completed |
NCT00185159 -
Olmesartan Medoxomil in Diabetes Mellitus
|
Phase 3 |